2023-01-24 12:00:00

CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Logo GlobeNewswire

NEWARK, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced the pricing of its previously announced underwritten public offering of common stock and pre-funded warrants. CymaBay is selling 10,000,000 shares of common stock and pre-funded warrants to purchase 2,142,857 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $7.00 per share, and the pre-funded warrants are being sold at a public offering price of $6.9999 per underlying share. The gross offering proceeds to CymaBay from this offering are expected to be approximately $85.0 million, before deducting the underwriting discount and other estimated offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering are being offered by CymaBay. CymaBay has granted the underwriters a 30-day option to purchase up to an additional 1,821,428 shares of its common stock at the public offering price per share less underwriting discounts and commissions. CymaBay anticipates using the net proceeds from the offering to fund ongoing development of seladelpar, including clinical trials targeting market expansion, and for working capital and general corporate purposes.

The offering is expected to close on January 26, 2023, subject to the satisfaction of customary closing conditions.

Piper Sandler, Raymond James and Cantor are acting as the joint book-running managers for the offering.

The securities described above are being offered by CymaBay pursuant to a shelf registration statement filed with the Securities and Exchange Commission (the "SEC"). A preliminary prospectus supplement and accompanying prospectus related to the offering has been filed, and a final prospectus supplement and accompanying prospectus related to the offering will be filed, with the SEC and are or will be available on the SEC's website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, from: Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at 800-747-3924, or by email at prospectus@psc.com; Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, by telephone at (800) 248-8863, or by e-mail at prospectus@raymondjames.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 4th Floor, New York, New York 10022, or by e-mail at prospectus@cantor.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About CymaBay

CymaBay Therapeutics, Inc. (Nasdaq: CBAY) is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies.

Cautionary Statements

This press release contains forward-looking statements, including statements relating to CymaBays expectations regarding the timing of the closing of the public offering and anticipated use of proceeds. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. CymaBay cautions investors not to place undue reliance on the forward-looking statements contained in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to the satisfaction of customary closing conditions related to the public offering. There can be no assurance that CymaBay will be able to complete the public offering on the anticipated terms, or at all. Risks and uncertainties relating to CymaBay and its business can be found in the Risk Factors section of CymaBays Form 10-Q for the quarter ended September 30, 2022, filed with the SEC on November 14, 2022, and in the preliminary prospectus supplement related to the offering filed with the SEC on January 23, 2023. CymaBay undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in CymaBays expectations.

Public Relations Contact:
Glenn Silver
Lazar-FINN Partners
(973) 818-8198

Investor Relations Contact:
Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578

Continue read on globenewswire.com

Logo GlobeNewswire
SciencePress Release2023-01-23 21:11:00
NEWARK, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing...

Logo GlobeNewswire
TechnologyPress Release2023-01-23 22:09:00
NEWPORT BEACH, Calif. and LEHI, Utah, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Verb Technology Company, Inc. (NASDAQ: VERB) ("VERB" or the "Company"), the leader in...

Logo Nasdaq
Business / FinanceBy Rtt News2023-01-23 12:10:29
(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) Monday said it is commencing a tender offer to buy all shares of CinCor Pharma, Inc. (CINC), a...

Logo PR Newswire
EntertainmentPress Release2023-01-23 23:20:00
LAS VEGAS and RENO, Nev., Jan. 23, 2023 /PRNewswire/ -- Caesars Entertainment, Inc. (NASDAQ: CZR) (the "Company," "Caesars" or the "Issuer") today announced...

Logo GlobeNewswire
SciencePress Release2023-01-24 12:00:00
EMERYVILLE, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the...

Logo PR Newswire
HealthPress Release2023-01-24 11:30:00
DUBLIN, Jan. 24, 2023 /PRNewswire/ -- The "China Anti-Rheumatic Drug Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's...

Logo PR Newswire
EntertainmentPress Release2023-01-23 13:00:00
LAS VEGAS and RENO, Nev., Jan. 23, 2023 /PRNewswire/ -- Caesars Entertainment, Inc. (NASDAQ: CZR) (the "Company") today announced that the Company, intends...

Logo RTTNews
EconomyBy Rtt News Staff Writer2023-01-24 11:56:38
The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 06.45 A.M. ET). In the Green SuperCom Ltd. ( SPCB ) is up over...

Logo NewsFileCorp
Press Release2023-01-23 14:00:00
Endorsement underscores transition into a fully integrated biotechnology company Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - Lobe...

Logo GlobeNewswire
EconomyPress Release2023-01-24 10:10:00
Major serverless architecture market participants are Alibaba Group Holding Limited, Alphabet (Google) Inc., Asseco Group, AWS (Amazon) Inc., Enfo Oyj,...

Logo Nasdaq
Business / FinanceBy Mt Newswires2023-01-23 14:13:11
Health care stocks were steady premarket Monday, with the Health Care Select Sector SPDR Fund ( XLV ) and the iShares Biotechnology ETF (IBB) unchanged....

Logo PR Newswire
HealthPress Release2023-01-23 13:00:00
ST. LOUIS, Jan. 23, 2023 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today that it has completed the previously announced divestiture of...

Logo GlobeNewswire
SciencePress Release2023-01-23 14:20:00
The Company is expected to evaluat e alternatives to address potential short sales issue TEL AVIV, Israel, Jan. 23, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd....

Logo Inquirer.net
Business / FinanceBy Miguel R Camus2023-01-23 18:06:00
Tycoon Alfredo Yaos Philippine Business Bank (PBB) is raising P500 million through a stock rights offer next month as it vies for a universal bank license...

Logo GlobeNewswire
DALLAS, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, and its board of directors...

Logo Nasdaq
Business / FinanceBy The Motley Fool2023-01-23 15:13:25
Motley Fool contributor Jamie Louko likes how Semrush (NYSE: SEMR), a small marketing technology company, is improving margins. With a large one-time cost...

Logo Nasdaq
Business / FinanceBy Bnk Invest2023-01-23 15:57:17
In trading on Monday, shares of Carnival Corp (Symbol: CCL) crossed above their 200 day moving average of $10.80, changing hands as high as $10.83 per share....

Logo PR Newswire
ATLANTA, Jan. 23, 2023 /PRNewswire/ -- D and Z Media Acquisition Corp. (NYSE: DNZ) (the "Company") today announced that it will redeem all of the outstanding...

Logo PR Newswire
KNOXVILLE, Tenn., Jan. 23, 2023 /PRNewswire/ -- Mountain Commerce Bancorp, Inc. (the "Company") (OTCQX: MCBI), the holding company for Mountain Commerce Bank...

Logo GlobeNewswire
NEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- TheNasdaqStock Market announced today that it will delist the common stock of Schmitt Industries, Inc. Schmitt...